Article
Hematology
Sara Beygi, George E. Duran, Sebastian Fernandez-Pol, Alain H. Rook, Youn H. Kim, Michael S. Khodadoust
Summary: Resistance to mogamulizumab in mycosis fungoides and Sezary syndrome is often associated with loss of CCR4 expression and emergence of CCR4 genomic alterations. This finding has significant implications for the management and monitoring of patients receiving mogamulizumab and the development of future CCR4-directed therapies.
Review
Cell Biology
Amy Xiao, Oleg E. Akilov
Summary: The loss of CD47 on aging cells signals macrophages to eliminate the target. CD47 acts as a "do-not-eat-me" sign that prevents macrophagal phagocytosis by interacting with its ligand SIRP alpha. Malignant lymphocytes highly express CD47, making them ideal candidates for targeted anti-CD47 therapies. There are various types of anti-CD47-SIRP alpha therapeutic molecules, including monoclonal antibodies, bioengineered proteins, miRNAs, and bispecific antibodies. Blocking the CD47-SIRP alpha axis in combination with targeting secondary tumor microenvironment (TME) may enhance the effectiveness of current immunotherapeutic approaches.
Article
Biochemistry & Molecular Biology
Minami Sakamoto, Tomomitsu Miyagaki, Hiroaki Kamijo, Tomonori Oka, Hikari Boki, Naomi Takahashi-Shishido, Hiraku Suga, Makoto Sugaya, Shinichi Sato
Summary: CD147 and CypA are overexpressed in tumor cells of mycosis fungoides and Sezary syndrome patients, and CypA is also expressed by epidermal keratinocytes in lesional skin. Serum CypA levels are elevated and correlated with disease severity markers. Anti-CD147 and/or anti-CypA antibodies can suppress the proliferation of CTCL cell lines by downregulating signaling pathways.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
Xiangjun Liu, Shanzhao Jin, Simeng Hu, Ruoyan Li, Haihao Pan, Yi Liu, Pan Lai, Deshu Xu, Jingru Sun, Ziyang Liu, Yumei Gao, Yifan Zhao, Fengjie Liu, Yu Xiao, Yingyi Li, Yujie Wen, Zhuojing Chen, Bufang Xu, Yuchieh Lin, Menglong Ran, Qianxi Li, Shuxia Yang, Hang Li, Ping Tu, Muzlifah Haniffa, Sarah A. Teichmann, Fan Bai, Yang Wang
Summary: Cutaneous T cell lymphoma (CTCL) is a heterogeneous group of non-Hodgkin lymphoma characterized by clonal malignant T cells. This study analyzed CTCL patient samples using single-cell RNA-seq, TCR and whole-exome sequencing, revealing the molecular profiles of malignant T cells and their association with the microenvironment and clinical outcomes.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Delice Kayishunge, Sophia Ly, Joseph Su, Henry K. Wong
Summary: This article presents a demographic and epidemiological analysis of CTCL patients in Arkansas and nationwide. The study found that CTCL primarily affects males, especially young black males. Additionally, the study identified certain geographic and environmental factors associated with CTCL.
Article
Dermatology
Sara Peru, Martina Prochazkova-Carlotti, Floriane Cherrier, Joanne Velazquez, Elodie Richard, Yamina Idrissi, David Cappellen, Lamia Azzi-Martin, Anne Pham-Ledard, Marie Beylot-Barry, Jean-Philippe Merlio, Sandrine Poglio
Summary: Cutaneous T-cell lymphoma (CTCL) is characterized by abnormal infiltration of T lymphocytes in the skin. In this study, the researchers found that the expression of cutaneous lymphocyte antigen (CLA) in CTCL cells is crucial for their migration and survival. The use of a CLA antibody significantly reduced the migration and survival of CTCL cells both in vitro and in vivo. These findings suggest that inhibiting CLA could be a potential therapeutic strategy for CTCL patients.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Article
Dermatology
Janika Gosmann, Rudolf Stadler, Koen D. Quint, Ralf Gutzmer, Maarten H. Vermeer
Summary: This study aimed to report on the efficacy, adverse events, and therapy regimens of PEG-IFN alpha in cutaneous T-cell lymphoma. Results showed that PEG-IFN alpha, especially in combination with skin-directed therapies, is an effective treatment option for cutaneous T-cell lymphoma in clinical practice.
ACTA DERMATO-VENEREOLOGICA
(2023)
Review
Dermatology
Kazuyasu Fujii
Summary: Mycosis fungoides (MF) and Sezary syndrome (SS) are representative cutaneous lymphomas, with a shift from Th1 to Th2 environment as the disease progresses. Staphylococcus aureus is highly sensitive in advanced stages, and susceptibility to infection is related to the main symptoms of MF.
JOURNAL OF DERMATOLOGY
(2022)
Article
Cell Biology
Loka Reddy Velatooru, Cheng Hui Hu, Pedram Bijani, Xiaohong Wang, Pierr Bojaxhi, Hao Chen, Madeleine Duvic, Xiao Ni
Summary: In this study, a novel JAK3-INSL3 fusion transcript was identified in cutaneous T-cell lymphomas (CTCL). Higher expression of JAK3-INSL3 was associated with poorer survival in CTCL patients. Knockdown of JAK3-INSL3 decreased cell proliferation and tumor growth.
Review
Medicine, Research & Experimental
Man Hu, Joerg Scheffel, Daniel Elieh-Ali-Komi, Marcus Maurer, Tomasz Hawro, Martin Metz
Summary: Primary cutaneous T-cell lymphomas (CTCL) are characterized by the accumulation of malignant T-lymphocytes in the skin, leading to severe pruritus that significantly impacts patients' quality of life. Understanding the underlying mechanisms of CTCL pruritus is challenging, but studies suggest that proteases (such as tryptase) and neuropeptides (particularly Substance P) may play a significant role, alongside cytokine receptors, MRGPRs, and TRP channels. Targeting these mediators and receptors could lead to effective treatment options for CTCL pruritus.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Cell Biology
Philipp Licht, Volker Mailaender
Summary: Cutaneous T-Cell Lymphomas (CTCL) exhibit clinical variability and transcriptional heterogeneity, with different T-cell subtypes suggested as sources of the disease. The microbiome may play a role in disease progression and transcriptional heterogeneity, and microbial approaches have the potential to aid in diagnosis and treatment of CTCL.
Article
Cell Biology
Xiaotong Xue, Zhenzhen Wang, Zihao Mi, Tingting Liu, Chuan Wang, Peidian Shi, Lele Sun, Yongliang Yang, Wenchao Li, Zhe Wang, Hong Liu, Furen Zhang
Summary: Sezary syndrome, a rare and aggressive type of cutaneous T cell lymphoma, poses challenges in diagnosis and treatment due to its intra-tumoral heterogeneity and poor understanding of its pathogenesis. Single-cell transcriptomic and chromatin accessibility data analysis revealed developmental differences and specific marker genes in Sezary cells from different sources, providing insights into the diagnosis and prognosis of MF/SS. Functional experiments demonstrated that targeting inhibition of KLHL42 could be a promising therapeutic approach in CTCL.
CELL DEATH & DISEASE
(2022)
Article
Dermatology
Cosimo Di Raimondo, Sara Vaccarini, Andrea Nunzi, Vito Rapisarda, Annagiulia Zizzari, Federico Meconi, Alessandro Monopoli, Maria Grazia Narducci, Enrico Scala, Luca Bianchi, Cristiano Tesei, Maria Cantonetti
Summary: The aim of this retrospective study was to assess the efficacy of a lower dosage of gemcitabine in treating cutaneous T cell lymphomas (CTCL). The study found that the schedule of 1000 mg every 15 days had the highest efficacy and lowest toxicity profile. Gemcitabine at a lower dose showed durable response in advanced-stage and refractory CTCL patients.
DERMATOLOGIC THERAPY
(2022)
Review
Oncology
Kalyani Patil, Shilpa Kuttikrishnan, Abdul Q. Khan, Fareed Ahmad, Majid Alam, Joerg Buddenkotte, Aamir Ahmad, Martin Steinhoff, Shahab Uddin
Summary: Cutaneous T cell lymphomas (CTCLs) are a diverse group of lymphoproliferative neoplasms with varying immune, clinical, and histopathological features. Recent studies have used next-generation sequencing (NGS) to reveal genetic and epigenetic abnormalities that contribute to the development of CTCL. Malignant T cell clones in CTCL patients secrete cytokines and chemokines, creating a tumor microenvironment that favors T helper 2 (Th2)-type immune responses and promotes immune dysregulation and tumor growth. Understanding the molecular mechanisms, including the role of cytokines, chemokines, and signaling networks, in CTCL pathogenesis can lead to new therapeutic approaches.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Dermatology
Yuka Mizuno, Sayaka Shibata, Tomomitsu Miyagaki, Yukiko Ito, Haruka Taira, Issei Omori, Teruyoshi Hisamoto, Kenta Oka, Kazuki M. Matsuda, Hikari Boki, Naomi Takahashi-Shishido, Makoto Sugaya, Shinichi Sato
Summary: In recent years, circulating cell-free DNA (cfDNA) has gained attention as a biomarker for cancer. This study found that serum cfDNA levels in patients with cutaneous T-cell lymphoma (CTCL) were significantly higher than healthy controls and increased with disease progression. There were positive correlations between cfDNA levels and certain blood markers and clinical findings, and higher cfDNA levels were associated with a worse prognosis in CTCL patients.
JOURNAL OF DERMATOLOGY
(2022)
Letter
Dermatology
Shinsuke Nakazawa, Pawit Phadungsakswasdi, Hazuki Kageyama, Kensuke Fukuchi, Takatoshi Shimauchi, Toshiharu Fujiyama, Taisuke Ito, Tetsuya Honda
JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Yasuaki Ogura, Kensuke Fukuchi, Hiroki Morimoto, Tsurumi Yuki, Masaki Otsuka, Takatoshi Shimauchi, Tetsuya Honda, Yoshiki Tokura
Summary: This study investigated the serum biomarkers associated with the pathogenesis of mamushi bites, revealing correlations between coagulation abnormalities, muscular damage, and neutrophil activation. Furthermore, the study suggested a novel cascade involving neutrophil activation leading to the production of IL-22 and VEGF, contributing to both vascular damage and repair in mamushi bites.
JOURNAL OF DERMATOLOGY
(2022)
Article
Oncology
Atae Utsunomiya, Koji Izutsu, Tatsuro Jo, Shinichiro Yoshida, Kunihiro Tsukasaki, Kiyoshi Ando, Ilseung Choi, Yoshitaka Imaizumi, Koji Kato, Mitsutoshi Kurosawa, Shigeru Kusumoto, Takashi Miyagi, Eiichi Ohtsuka, Osamu Sasaki, Hirohiko Shibayama, Kazuya Shimoda, Yasushi Takamatsu, Kuniko Takano, Kentaro Yonekura, Shinichi Makita, Jun Taguchi, Mireille Gillings, Hiroshi Onogi, Kensei Tobinai
Summary: This multicenter, prospective phase IIb trial evaluated the efficacy and safety of Tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATLL) in Japan. Results showed that Tucidinostat had a meaningful treatment effect for R/R ATLL patients, although adverse events were common.
Article
Hematology
Koji Izutsu, Shinichi Makita, Kisato Nosaka, Makoto Yoshimitsu, Atae Utsunomiya, Shigeru Kusumoto, Satoko Morishima, Kunihiro Tsukasaki, Toyotaka Kawamata, Takaaki Ono, Shinya Rai, Hiroo Katsuya, Jun Ishikawa, Hironori Yamada, Kazunobu Kato, Masaya Tachibana, Yasuyuki Kakurai, Nobuaki Adachi, Kensei Tobinai, Kentaro Yonekura, Kenji Ishitsuka
Summary: This study evaluated the efficacy and safety of valemetostat, an inhibitor of EZH2 and EZH1, in treating relapsed or refractory ATL. The results showed that valemetostat demonstrated promising efficacy and tolerability in heavily pretreated patients with R/R ATL, warranting further investigation.
Letter
Dermatology
Reiko Kageyama, Taisuke Ito, Shinsuke Nakazawa, Takatoshi Shimauchi, Toshiharu Fujiyama, Tetsuya Honda
JOURNAL OF DERMATOLOGY
(2023)
Article
Oncology
Takaaki Ono, Naoto Takahashi, Masahiro Kizaki, Tatsuya Kawaguchi, Ritsuro Suzuki, Kazuhito Yamamoto, Kazunori Ohnishi, Tomoki Naoe, Itaru Matsumura
Summary: Age and comorbidities should be taken into consideration when selecting TKIs for first-line treatment in CML-CP patients. This study found that the choice between imatinib and second-generation TKIs did not significantly impact treatment outcomes, regardless of age. However, older patients had lower overall survival rates compared to younger patients.
Article
Oncology
Michael L. Wang, Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, James N. Gerson, Ian Flinn, Benoit Tessoulin, Alvaro J. Alencar, Shuo Ma, David Lewis, Ewa Lech-Maranda, Joanna Rhodes, Krish Patel, Kami Maddocks, Nicole Lamanna, Yucai Wang, Constantine S. Tam, Talha Munir, Hirokazu Nagai, Francisco Hernandez-Ilizaliturri, Anita Kumar, Timothy S. Fenske, John F. Seymour, Andrew D. Zelenetz, Binoj Nair, Donald E. Tsai, Minna Balbas, Richard A. Walgren, Paolo Abada, Chunxiao Wang, Junjie Zhao, Anthony R. Mato, Nirav N. Shah
Summary: This study evaluated the safety and efficacy of Pirtobrutinib, a noncovalent BTK inhibitor, in patients with mantle-cell lymphoma who had previously received covalent BTK inhibitors. The results showed that Pirtobrutinib demonstrated durable efficacy and was well tolerated in this heavily pretreated patient population.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Dermatology
Atsuyoshi Ginoza, Reiko Kageyama, Norihito Suzuki, Takatoshi Shimauchi, Toshiharu Fujiyama, Taisuke Ito, Tetsuya Honda
JOURNAL OF DERMATOLOGY
(2023)
Letter
Allergy
Izumi Takei, Kazuhiro Kawai, Mihoko Yamazaki
JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY
(2023)
Letter
Biophysics
Risa Koresawa-Shimizu, Ritsuro Suzuki, Yasufumi Uehara, Nobuhiro Hiramoto, Masashi Sawa, Takahiro Fukuda, Keisuke Kataoka, Yoshinobu Kanda, Tatsuo Oyake, Yasushi Kubota, Naoyuki Uchida, Shingo Yano, Hikaru Kobayashi, Junji Tanaka, Yoshiko Atsuta, Eisei Kondo
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Koji Izutsu, Takahiro Kumode, Junichiro Yuda, Hirokazu Nagai, Yuko Mishima, Youko Suehiro, Kazuhito Yamamoto, Tomoaki Fujisaki, Kenji Ishitsuka, Kenichi Ishizawa, Takayuki Ikezoe, Momoko Nishikori, Daigo Akahane, Jiro Fujita, Minh Dinh, David Soong, Hidehisa Noguchi, Jeppe Klint Buchbjerg, Elena Favaro, Noriko Fukuhara
Summary: This study presented the results of epcoritamab monotherapy in Japanese patients, showing durable treatment responses and manageable safety profile. The drug has potential therapeutic effects in relapsed or refractory diffuse large B-cell lymphoma.
Letter
Hematology
Koji Izutsu, Kazuhito Yamamoto, Koji Kato, Takayuki Ishikawa, Noriko Fukuhara, Yasuhito Terui, Ilseung Choi, Sumiko Okubo, Natsumi Ogawa, Mizu Sakai, Yasuko Nishimura, Brenda Chyla, Yan Sun, Dai Maruyama
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2023)
Letter
Dermatology
Kana Terao, Kazuhiro Kawai, Izumi Takei
JOURNAL OF DERMATOLOGY
(2023)
Article
Oncology
Wataru Munakata, Koji Izutsu, Yuko Mishima, Hirokazu Nagai, Yuko Ishihara, Junji Suzumiya, Yuzuru Kanakura, Toshihiro Nanki, Takeshi Miyake, Atsuko Kawasaki, Tatsuya Yoshinaga, Kenichi Ishizawa
Summary: This study assessed the tolerability, safety, and pharmacokinetics of mosunetuzumab in Japanese patients with relapsed/refractory B-cell NHL. The results demonstrated that mosunetuzumab has acceptable safety and antitumor activity in Japanese patients, and the recommended Phase II dose was identified.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Carla Casulo, Armando Santoro, Guillaume Cartron, Kiyoshi Ando, Javier Munoz, Steven Le Gouill, Koji Izutsu, Simon Rule, Pieternella Lugtenburg, Jia Ruan, Luca Arcaini, Marie-Laure Casadebaig, Brian Fox, Nurgul Kilavuz, Nils Rettby, Justine Dell'Aringa, Lilia Taningco, Richard Delarue, Myron Czuczman, Thomas Witzig
Summary: The immune checkpoint inhibitor durvalumab shows potential as a strategy for enhancing immune responses and improving standard therapies in patients with hematologic malignancies. This study evaluated the safety and efficacy of durvalumab in combination with standard-of-care therapies for lymphoma or chronic lymphocytic leukemia (CLL) and found limited benefits of durvalumab monotherapy or combination therapy.
